{
    "topic": "coronavirus",
    "source": "The Hill",
    "bias": 1,
    "url": "https://thehill.com/policy/healthcare/498261-moderna-reports-positive-results-from-early-data-on-coronavirus-vaccine",
    "title": "Moderna reports 'positive' results from early data on coronavirus vaccine",
    "date": "2020-05-18",
    "authors": "",
    "content": "The biotech company Moderna on Monday reported \u201c positive \u201d data on its potential coronavirus vaccine from an early clinical trial , raising hopes about the effort .\nThe company said early data from a phase one clinical trial showed that people given the potential vaccine generated an immune response similar to that in people who had recovered from the disease .\nThe levels of neutralizing antibodies were \u201c at or above \u201d the levels seen in blood samples from people who have recovered from the coronavirus , Moderna said in a statement .\nStill , that early result is only from the first eight participants in the trial .\n\u201c These interim Phase 1 data , while early , demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 [ micrograms ] , \u201d Tal Zaks , chief medical officer at Moderna , said in a statement .\n\u201c These data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials , \u201d he added , referring to the potential vaccine .\nThe company also said the vaccine was \u201c generally safe and well tolerated. \u201d All side-effects , including redness in one participant around the injection site , have so far been \u201c transient and self-resolving , \u201d the company noted , adding that no \u201c serious \u201d side-effects have been reported .\nAdditionally , the potential vaccine was successful in preventing the virus from replicating in mice \u2019 s lungs in another study , Moderna said .\nThe company , which is working with the National Institute of Allergy and Infectious Diseases , led by Anthony Fauci Anthony FauciCelebs including Julia Roberts , Hugh Jackman let health experts take over their social media to talk COVID-19 Trying to protect everyone , we exposed the most vulnerable to the virus Moderna CEO says coronavirus vaccine could be ready by end of year MORE , is about to begin a phase two trial and said it hopes to begin a phase three trial in July .\n\u201c We are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from SARS-CoV-2 , \u201d said the company \u2019 s CEO , St\u00e9phane Bancel .",
    "content_original": "The biotech company Moderna on Monday reported \u201cpositive\u201d data on its potential coronavirus vaccine from an early clinical trial, raising hopes about the effort.\n\nThe company said early data from a phase one clinical trial showed that people given the potential vaccine generated an immune response similar to that in people who had recovered from the disease.\n\nThe levels of neutralizing antibodies were \u201cat or above\u201d the levels seen in blood samples from people who have recovered from the coronavirus, Moderna said in a statement.\n\nADVERTISEMENT\n\nStill, that early result is only from the first eight participants in the trial.\n\n\u201cThese interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 [micrograms],\u201d Tal Zaks, chief medical officer at Moderna, said in a statement.\n\n\u201cThese data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials,\u201d he added, referring to the potential vaccine.\n\nThe company also said the vaccine was \u201cgenerally safe and well tolerated.\u201d All side-effects, including redness in one participant around the injection site, have so far been \u201ctransient and self-resolving,\u201d the company noted, adding that no \u201cserious\u201d side-effects have been reported.\n\nAdditionally, the potential vaccine was successful in preventing the virus from replicating in mice\u2019s lungs in another study, Moderna said.\n\nThe company, which is working with the National Institute of Allergy and Infectious Diseases, led by Anthony Fauci Anthony FauciCelebs including Julia Roberts, Hugh Jackman let health experts take over their social media to talk COVID-19 Trying to protect everyone, we exposed the most vulnerable to the virus Moderna CEO says coronavirus vaccine could be ready by end of year MORE, is about to begin a phase two trial and said it hopes to begin a phase three trial in July.\n\n\u201cWe are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from SARS-CoV-2,\u201d said the company\u2019s CEO, St\u00e9phane Bancel.\n\nUpdated at 8:25 a.m.",
    "source_url": "www.thehill.com",
    "bias_text": "center",
    "ID": "Ob3pA2spPrhx5cHg"
}